Compare IDAI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | NXL |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.6M |
| IPO Year | N/A | 2022 |
| Metric | IDAI | NXL |
|---|---|---|
| Price | $3.89 | $0.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $5.00 |
| AVG Volume (30 Days) | 93.7K | ★ 156.8K |
| Earning Date | 11-14-2025 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,727,824.00 | $156,931.00 |
| Revenue This Year | $3.46 | $38.28 |
| Revenue Next Year | $219.85 | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 72.57 | N/A |
| 52 Week Low | $1.43 | $0.54 |
| 52 Week High | $5.28 | $3.87 |
| Indicator | IDAI | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 36.59 |
| Support Level | $3.80 | $0.58 |
| Resistance Level | $4.31 | $0.77 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 17.54 | 11.32 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.